Ontology type: schema:ScholarlyArticle
2012-04
AUTHORS ABSTRACTDemonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab as first-line therapy and discuss the optimum use of the drug in this disease.
PAGES194
http://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28
DOIhttp://dx.doi.org/10.1038/nrclinonc.2012.28
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1017213493
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/22371131
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Angiogenesis Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal, Humanized",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bevacizumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Clinical Trials as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ovarian Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prognosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Standard of Care",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Royal Marsden NHS Foundation Trust",
"id": "https://www.grid.ac/institutes/grid.5072.0",
"name": [
"The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JB, UK"
],
"type": "Organization"
},
"familyName": "Banerjee",
"givenName": "Susana",
"id": "sg:person.01326353035.21",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326353035.21"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Royal Marsden Hospital",
"id": "https://www.grid.ac/institutes/grid.424926.f",
"name": [
"The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK"
],
"type": "Organization"
},
"familyName": "Kaye",
"givenName": "Stan B.",
"id": "sg:person.010545363662.22",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010545363662.22"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/s0959-8049(11)70155-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017540844"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ygyno.2007.01.038",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023390376"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrclinonc.2011.32",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027641359",
"https://doi.org/10.1038/nrclinonc.2011.32"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2012.42.0505",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028708792"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2012.42.0505",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028708792"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1104390",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035779003"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1104390",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035779003"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1103799",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052109861"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1103799",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052109861"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2011.29.18_suppl.lba5007",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1083951206"
],
"type": "CreativeWork"
}
],
"datePublished": "2012-04",
"datePublishedReg": "2012-04-01",
"description": "Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab as first-line therapy and discuss the optimum use of the drug in this disease.",
"genre": "non_research_article",
"id": "sg:pub.10.1038/nrclinonc.2012.28",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1034153",
"issn": [
"1759-4774",
"1759-4782"
],
"name": "Nature Reviews Clinical Oncology",
"type": "Periodical"
},
{
"issueNumber": "4",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "9"
}
],
"name": "Gynecological cancer: First-line bevacizumab for ovarian cancer\u2014new standard of care?",
"pagination": "194",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"520348fc0da1faf9b5f55615c0a5dd84f6b78188e712be0d94fe7b26ccde9064"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"22371131"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101500077"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/nrclinonc.2012.28"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1017213493"
]
}
],
"sameAs": [
"https://doi.org/10.1038/nrclinonc.2012.28",
"https://app.dimensions.ai/details/publication/pub.1017213493"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T15:41",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000451.jsonl",
"type": "ScholarlyArticle",
"url": "https://www.nature.com/articles/nrclinonc.2012.28"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28'
This table displays all metadata directly associated to this object as RDF triples.
137 TRIPLES
21 PREDICATES
45 URIs
30 LITERALS
18 BLANK NODES